CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 48 enrolled
Drug / intervention
matrix metalloproteinase enzymes 2 and 9other
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04773028
NCT04773028N/ACompleted
CompareCT.gov

The Role of Matrix Metalloproteinase 2 and 9 Enzymes in Developing Chronic Thromboembolic Pulmonary Hypertension

AHMET ZENGIN·observational·Posted Feb 26, 2021·Updated Aug 10, 2021

In Brief

An observational study evaluating matrix metalloproteinase enzymes 2 and 9 for Chronic Thromboembolic Pulmonary Hypertension. Completed, enrolled 48 participants across 1 site.

Detailed Summary

Chronic thromboembolic pulmonary hypertension is an occlusive disease in pulmonary artery.Matrix metalloproteinase enzymes play a substantial role of extracellular matrix remodeling. The clot formed in chronic thromboembolic pulmonary hypertension does not melt and turns into a fibrous state, it occludes the pulmonary artery.In this study, investigators aimed to investigate the role of matrix metalloproteinase enzymes in pulmonary arterial wall remodeling in patients with chronic thromboembolic pulmonary hypertension

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Thromboembolic Pulmonary Hypertension
CountriesTurkey (Türkiye)
Collaborators--

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedFeb 26, 2021
Enrollment StartJul 1, 2020
Primary CompletionMay 4, 2021
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 5.4 years ago

Interventions

matrix metalloproteinase enzymes 2 and 9other

concentration of matrix metalloproteinase 2 and 9 enzymes